Table 3.
Characteristics of classical Hodgkin and large B-cell lymphomas in outpatient and inpatient cohorts
| Classical Hodgkin lymphoma (N = 318) | Large B-cell lymphoma (N = 578) | |||||
|---|---|---|---|---|---|---|
| Characteristic | OPs 1 (n = 216) | IPs 2 (n = 102) | P value 1 vs 2 | OPs 1 (n = 369) | IPs 2 (n = 209) | P value 1 vs 2 |
| Age (years), mean (SD) | 43.6 (15.8) | 51.7 (13.3) | <.001 | 65.1 (17.5) | 69.7 (15.5) | <.001 |
| < 45, n (%) | 113 (52.3) | 44 (43.1) | <.001 | |||
| ≥ 45, n (%) | 103 (47.7) | 58 (56.9) | <.001 | |||
| ≤ 60, n (%) | 121 (32.8) | 28 (13.4) | <.001 | |||
| > 60, n (%) | 248 (67.2) | 181 (86.6) | <.001 | |||
| Sex, n (%) | ||||||
| Females | 98 (45.4) | 42 (41.2) | .069 | 156 (42.3) | 84 (40.2) | .104 |
| Males | 118 (54.6) | 60 (58.8) | .074 | 213 (57.7) | 125 (59.8) | .091 |
| Clinical manifestations, n (%) | ||||||
| Lymphadenopathy | 152 (70.4) | 51 (50.0) | <.001 | 246 (66.7) | 95 (45.5) | <.001 |
| Systemic symptoms | 51 (23.6) | 39 (38.2) | <.001 | 101 (27.4) | 86 (41.1) | <.001 |
| Pain symptoms | 9 (4.2) | 8 (7.8) | .084 | 11 (3.0) | 16 (7.7) | .025 |
| Chest symptoms | 3 (1.4) | 2 (2.0) | .190 | 8 (2.2) | 8 (3.8) | .120 |
| Other symptoms/signs | 1 (0.0) | 2 (2.0) | .131 | 3 (0.8) | 4 (1.9) | .135 |
| Successive/first visit ratio | 2.10 | 2.33 | ||||
| QDU time for diagnosis /admission time for diagnosis (days), mean (SD) | 15.5 (1.7) | 11.3 (2.7) | .030 | 16.7 (2.2) | 13 (2.5) | .001 |
| Suspected/compatible lymphoma by FNAC, n (%)/total n | 72 (52.9) /136 | 21 (52.5)/40 | .203 | 156 (71.9)/217 | 35 (71.4)/49 | .155 |
| Time to FNAC (days), mean (SD) | 1.3 (0.6) | 1.1 (0.4) | .130 | 1.3 (0.7) | 1.2 (0.5) | .125 |
| Time to excisional biopsy (days), mean (SD) | 7.3 (1.3) | 3.3 (0.9) | <.001 | 7.1 (1.3) | 3.6 (0.9) | .003 |
| ECOG performance score > 1, n (%)/total n | 31 (15.6)/199 | 21 (21.2)/99 | .045 | 70 (20.8)/336 | 53 (27.5)/193 | <.001 |
| B symptoms, n (%)a | 68 (31.4) | 39 (38.2) | .002 | 107 (29.0) | 71 (34.0) | .021 |
| Serum LDH > UNL, n (%) | 30 (13.9) | 18 (17.6) | .082 | 184 (49.9) | 119 (56.9) | <.001 |
| Bulky disease, n (%)/total nb | 44 (22.4)/196 | 27 (28.7)/94 | .010 | 86 (24.9)/345 | 63 (31.5)/200 | .001 |
| Extranodal disease, n (%)c | 33 (15.3) | 20 (19.6) | .061 | |||
| > 1 extranodal site, n (%) | 99 (26.8) | 69 (33.0) | .009 | |||
| Ann Arbor stage, n (%) | ||||||
| I-II | 142 (65.7) | 60 (58.8) | .002 | 157 (42.5) | 71 (34.0) | <.001 |
| III-IV | 74 (34.3) | 42 (41.2) | .001 | 212 (57.5) | 138 (66.0) | <.001 |
| IPS score (advanced-stage diseasedd), n (%)/total n | ||||||
| Low risk (≤ 3) | 166 (84.7)/196 | 74 (78.7)/94 | .035 | |||
| High risk (≥ 4) | 30 (15.3)/196 | 20 (21.3)/94 | .042 | |||
| IPI score, n (%)/total n | ||||||
| Low risk (0-1) | 114 (33.9)/336 | 52 (26.9)/193 | <.001 | |||
| Intermediate risk (2-3) | 158 (47.0)/336 | 92 (47.7)/193 | .144 | |||
| High risk (4-5) | 64 (19.0)/336 | 49 (25.4)/193 | .004 | |||
Abbreviations: OPs total number of outpatients from the quick diagnosis units of the Hospital Clínic and the Hospital of Bellvitge; ECOG Eastern Cooperative Oncology Group; LDH lactate dehydrogenase; UNL upper normal limit; IPS international prognostic score; IPI international prognostic index. For other abbreviations, see Table 1
aRecurrent fever, night sweats, or > 10% weight loss; b ≥ 10 cm largest diameter; cInvolvement of extra lymphatic tissue; dAdvanced-stage disease was defined as stage III or IV disease or stage I or II with bulky disease or stage II disease with B symptoms [59]
For other definitions and explanations, see Table 1 Missing data: variables ‘time to FNAC’ (classical Hodgkin lymphoma: OPs = 5, IPs = 3; large B-cell lymphoma: OPs = 7, IPs = 5), ‘time to excisional biopsy’ (classical Hodgkin lymphoma: OPs = 0, IPs = 1; large B-cell lymphoma: OPs = 3, IPs = 1), ‘B symptoms’ (classical Hodgkin lymphoma: OPs = 2, IPs = 1; large B-cell lymphoma: OPs = 4, IPs = 3)